Literature DB >> 31466705

Skin immunization with third-generation hepatitis B surface antigen using microneedles.

Thuy Trang Nguyen1, Jung-Ah Choi2, Ji Seok Kim1, Hayan Park2, Eunji Yang2, Won Jun Lee1, Seung-Ki Baek3, Manki Song4, Jung-Hwan Park5.   

Abstract

L-HBsAg is a third-generation hepatitis vaccine capable of inducing antibodies in non-responders and thus providing potentially therapeutic treatment. In this study, L-HBsAg was administered using microneedles (MN) without an adjuvant to induce intradermal (ID) immunization, and the efficacy of ID immunization was compared with that of intramuscular (IM) immunization that uses a conventional formulation with an adjuvant of aluminum hydroxide (L-HBsAg-AL-IM). The L-HBsAg was dip-coated onto 800-μm-long microneedles made of polylactic acid (PLA). Delivery efficiency and administration time were determined through in vitro experiments using porcine skin. The denaturation of the formulation against sterilization by gamma rays was observed. A storage test and a freeze-thaw cycle test of the microneedles with trehalose as a stabilizer (L-HBsAg-MN-Tre) were observed. An antibody titer of L-HBsAg-MN-Tre was compared with that of the conventional IM immunization of the L-HBsAg solution with aluminum hydroxide (L-HBsAg-AL-IM). The formulation containing L-HBsAg was located on the upper third of the microneedle tips. The formulation on the MN was dissolved and delivered within 30 min of insertion into porcine skin in vitro. Trehalose was selected as a stabilizer, and the stabilizing effect increased with the increase of trehalose content in the solidified formulation. L-HBsAg-MN with 15% of trehalose was stable for 7 days at 40 °C and showed increased stability compared to the conventional liquid formulations. L-HBsAg-MN-Tre showed improved stability during the freeze-thaw cycle. The antibody titer of L-HBsAg-MN-Tre at 28 days was higher than that of L-HBsAg-AL-IM. ID administration of L-HBsAg-MN-Tre showed better efficacy and improved thermal and freeze thaw stability compared to L-HBsAg-AL-IM. Therefore, L-HBsAg-MN-Tre administration showed the possibility of ID delivery of L-HBsAg without the use of an adjuvant for the efficacy, convenience, and safety of pediatric vaccination.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Microneedles; Skin immunization; Third-generation hepatitis B surface antigen (L-HBsAg)

Year:  2019        PMID: 31466705     DOI: 10.1016/j.vaccine.2019.08.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.

Authors:  Emrullah Korkmaz; Stephen C Balmert; Cara Donahue Carey; Geza Erdos; Louis D Falo
Journal:  Expert Opin Drug Deliv       Date:  2020-10-06       Impact factor: 8.129

2.  Progress in microneedle array patch (MAP) for vaccine delivery.

Authors:  Thuy Trang Nguyen; Yujeong Oh; Yunseo Kim; Yura Shin; Seung-Ki Baek; Jung-Hwan Park
Journal:  Hum Vaccin Immunother       Date:  2020-07-15       Impact factor: 3.452

Review 3.  Microarray patches enable the development of skin-targeted vaccines against COVID-19.

Authors:  Emrullah Korkmaz; Stephen C Balmert; Tina L Sumpter; Cara Donahue Carey; Geza Erdos; Louis D Falo
Journal:  Adv Drug Deliv Rev       Date:  2021-02-02       Impact factor: 17.873

Review 4.  Microneedle for transdermal drug delivery: current trends and fabrication.

Authors:  Jae Hwan Jung; Sung Giu Jin
Journal:  J Pharm Investig       Date:  2021-03-04

5.  Evaluation of efficacy and safety of intradermal delivery of vaccines through microneedle(s) in human beings: a protocol for a systematic review.

Authors:  Ishumeet Kaur Bajwa; Navneet Kaur; Jeanne M Dsouza; Joseph L Mathew
Journal:  Syst Rev       Date:  2022-08-13

Review 6.  Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.

Authors:  Ana Sara Cordeiro; Yogita Patil-Sen; Maitreyi Shivkumar; Ronak Patel; Abdulwahhab Khedr; Mohamed A Elsawy
Journal:  Pharmaceutics       Date:  2021-12-05       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.